Diffuse Hemispheric Glioma, H3G34 Mutant: Clinical Trials

1 not yet recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	1	Not yet recruiting 1
Phase 2	1	Not yet recruiting 1

Follow Diffuse Hemispheric Glioma, H3G34 Mutant: new trials by email Literature Review of Diffuse Hemispheric Glioma, H3G34 Mutant trials Research Report on Diffuse Hemispheric Glioma, H3G34 Mutant

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV)	Phase 1 / Phase 2	Not yet recruiting	Sabine Mueller, MD, PhD	97	2027-06-01	2026-09-15

Narrower conditions

Glioblastoma (1)  ·  Glioma (1)

Broader conditions

Astrocytoma (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms, Germ Cell and Embryonal (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Neoplasms, Nerve Tissue (1)  ·  Neoplasms, Neuroepithelial (1)  ·  Neuroectodermal Tumors (1)

Interventions

ADI PEG20 (1)  ·  Temozolomide (1)

Sponsors

Sabine Mueller, MD, PhD (1)

Countries

United States (1)

Top investigators

Sabine Mueller, MD, PhD (1)  ·  Tom Davidson, MD (1)